Bio-Rad buys Quantase

Leading provider of specialty diagnostics acquires additional newborn screening tests to strengthen its broad portfolio of genetic disorders testing products and services

Bio-Rad Laboratories has acquired Quantase of Perth, Scotland, a company specialising in newborn screening diagnostic products.

Terms of the acquisition were not disclosed.

This acquisition strengthens Bio-Rad as a market leader in newborn screening tests for phenylketonuria, galactosemia, glucose-6-phosphate dehydrogenase (G-6-PD) deficiency.

It also enhances the company's leading position in genetic disorders testing by adding to its portfolio of DNA, immunoassay, and HPLC-based tests for sickle cell anaemia, metabolic disorders, and thalassemia.

"This acquisition strengthens our position in serving the genetic screening market and provides a foundation for us to further our innovation in genetic screening products and services," said David Schwartz, president of Bio-Rad Laboratories.

"Quantase has an excellent reputation for quality products and broad customer acceptance throughout the world." The current market for newborn screening tests is estimated to be more than $100 million worldwide and is growing at a rate of approximately 10% per year.

Newborn genetic screening is compulsory in the United States and in most developed nations around the world.

Back to top